PTPRC and melanoma: Other groups have identified CD279 (PD-1) expression in CD8+ T cells as a marker of clinical response after αPD-1/αCTLA-4 treatment in patients with melanoma (32–37); therefore, our panel also enables quantification of CD45+ CD3+ CD4- CD8+ CD279+ events.